Cognitive performance and lifetime cannabis use in patients with first-episode schizophrenia spectrum disorder

• Published in: Cognitive neuropsychiatry 2021-07, Vol.26 (4), p.257-272
• Main Authors: Hájková, M., Knížková, K., Siroňová, A., Keřková, B., Jonáš, J., Šustová, P., Dorazilová, A., Rodriguez, M.
• Format: Article
• Language: English
• Subjects: cannabis; cognition; Marijuana; psychosis; Schizophrenia; substance use
• ISSN: 1354-6805; 1464-0619
• DOI: 10.1080/13546805.2021.1924649

Cognitive impairment is among the core features of schizophrenia. In a healthy population, the cognitive deficit is often linked with cannabis abuse, and although the same would be expected in patients with schizophrenia, research has presented contradictory results. Participants were patients with first-episode schizophrenia (FES) spectrum disorder who had been lifetime cannabis users (N = 30), FES non-users (N = 53) as well as healthy controls (HC) also divided into cannabis users (N = 20) and non-users (N = 49). All participants underwent an extensive neurocognitive assessment and filled in a cannabis questionnaire, which allowed for a comparison of the four groups on cognitive functioning. FES patients using cannabis showed less impaired cognitive functioning with the most prominent difference in visual memory compared to FES non-users. However, they differed neither in the clinical assessment of general psychopathology, positive and negative symptoms, nor in medication from the patient's non-users. A comparison of the HC who used cannabis, and those who did not, revealed no sizeable differences in cognitive performance between the groups. The results delivered supporting evidence for the trend of superior neurocognitive performance in FES patients with a lifetime history of cannabis use compared to non-using patients.